Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M519Revenue (TTM) $M107Net Margin (%)-75.3Altman Z-Score-3.9
Enterprise Value $M513EPS (TTM) $-0.6Operating Margin %-76.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score8.7Pre-tax Margin (%)-75.3Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.2Cash flow > EarningsN
Price/Sales4.85-y EBITDA Growth Rate %--Current Ratio3.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-40.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-373.1Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M143ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with ARRY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARRYKen Fisher 2015-09-30 Buy $4.56 - $7.11
($5.94)
$ 3.62-39%New holding135,695
ARRYFirst Eagle Investment 2011-12-31 Sold Out -0.0024%$1.77 - $2.83
($2.27)
$ 3.6259%Sold Out0
ARRYGeorge Soros 2011-12-31 Sold Out -0.0008%$1.77 - $2.83
($2.28)
$ 3.6259%Sold Out0
ARRYGeorge Soros 2011-09-30 Buy $1.99 - $2.62
($2.24)
$ 3.6262%New holding22,400
ARRYFirst Eagle Investment 2011-06-30 Add$2.06 - $3.21
($2.7)
$ 3.6234%Add 150.00%250,000
ARRYGeorge Soros 2011-06-30 Sold Out $2.06 - $3.21
($2.7)
$ 3.6234%Sold Out0
ARRYFirst Eagle Investment 2011-03-31 Buy $2.7 - $3.29
($3)
$ 3.6221%New holding100,000
ARRYGeorge Soros 2011-03-31 Buy $2.7 - $3.29
($3)
$ 3.6221%New holding14,400
ARRYFirst Eagle Investment 2010-09-30 Sold Out -0.01%$2.67 - $3.44
($3.02)
$ 3.6220%Sold Out0
ARRYFirst Eagle Investment 2010-06-30 Reduce-0.01%$2.66 - $4.02
($3.41)
$ 3.626%Reduce -54.96%450,000
ARRYFirst Eagle Investment 2009-12-31 Add0.01%$1.72 - $2.81
($2.2)
$ 3.6265%Add 62.96%999,132
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARRY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARRY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Redmile Group, LLC10% Owner 2016-01-20Buy300,000$3.1913.48view
Redmile Group, LLC10% Owner 2016-01-12Buy75,000$3.60.56view
Redmile Group, LLC10% Owner 2016-01-11Buy925,000$3.67-1.36view
Redmile Group, LLC10% Owner 2015-10-01Buy782,592$4.58-20.96view
Redmile Group, LLC10% Owner 2015-10-01Buy600,140$4.58-20.96view
Redmile Group, LLC10% Owner 2015-08-26Buy49,900$5.48-33.94view
Redmile Group, LLC10% Owner 2015-08-25Buy790,000$5.38-32.71view
Redmile Group, LLC10% Owner 2015-08-12Buy532,500$5.88-38.44view
Redmile Group, LLC10% Owner 2015-08-10Buy1,048,993$5.8-37.59view
BAUM CHARLES MDirector 2015-05-08Sell25,000$7.38-50.95view

Quarterly/Annual Reports about ARRY:

News about ARRY:

Articles On GuruFocus.com
Screen: Stocks With Estimated Revenue Up 5% - January Jan 18 2016 
Insider Buys Round-up: Tenet Healthcare and Sprint Corp Aug 14 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 

More From Other Websites
Biotech Equities Technical Briefing on Array BioPharma, Geron, Emergent BioSolutions, and Global... Jul 18 2016
Array BioPharma To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference Jul 07 2016
Why These Stocks Are Trending on Friday Jul 01 2016
Why Array Is Making a Run Jul 01 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 30 2016
4:01 pm Array Biopharma submits NDA for binimetinib in patients with advanced NRAS-mutant melanoma... Jun 30 2016
Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA Jun 30 2016
Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : June 28,... Jun 28 2016
Array BioPharma, Inc. – Value Analysis (NASDAQ:ARRY) : June 17, 2016 Jun 17 2016
Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : June 16,... Jun 16 2016
All You Need To Know About Array Biopharma Inc (ARRY)’s Upcoming NDA Submission Jun 08 2016
Array Presents Full Results from Phase 3 NEMO Study Jun 06 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 06 2016
Array Presents Full Results from Phase 3 NEMO Study Jun 06 2016
Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant mCRC Phase III Trial Jun 04 2016
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial Jun 04 2016
Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal... Jun 04 2016
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial Jun 04 2016
Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal... Jun 04 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)